Acalabrutinib for treating relapsed or refractory mantle cell lymphoma [ID6389]
Awaiting development
Reference number: GID-TA11470
Expected publication date: TBC
Following on from advice received from the company, timelines for this appraisal are to be confirmed.
As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.